Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.

ABSTRACT:

SUBMITTER: Diefenbach CS 

PROVIDER: S-EPMC7737486 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature